Cancer treatment is complex. The widely varying progressions of this disease require comprehensive diagnostics, an early check of treatment, and the exchange of information with colleagues. The new version of the diagnostics software syngo.via supports the treating physician in making decisions regarding treatment in oncology through a comprehensive portfolio of applications across imaging systems, treatments, and disciplines.
Imaging procedures play an important role in treatment planning. Multimodal image material not only provides information for a precise assessment of the tumor with regard to its position, morphology and metabolism, but it also forms the basis for radiotherapy planning. The application syngo.via RT Image Suite supports the radiotherapy oncologists in the demanding task of optimally using clinical images from various sources such as CT, MRT or PET-CT in order to contour the tumor to be irradiated and the surrounding tissue to be spared.
Another part of the oncology software portfolio is the application syngo.MR OncoCare. It allows an early, quantitative evaluation of the response of the tumor to the treatment. Thus, conclusions can be drawn about the success of the selected treatment method and, if necessary, this method can be adapted. Thus, the patient is spared from the continuation of ineffective treatment and the unnecessary costs associated with it.
In order to define the best possible treatment for each individual patient and successfully treat cancer, a wide variety of medical disciplines are drawn upon. Their representatives come together in regular, interdisciplinary meetings on this topic in so-called tumor boards. Syngo.MI Offline Oncoboard provides an IT solution in order to be able to present syngo.via findings of the various imaging procedures even on a standard PC and independently of a network connection.
syngo.via can be used as a standalone device or together with a variety of syngo.via-based software options, which are medical devices in their own right. syngo.via and the syngo.via based software options are not commercially available in all countries. Due to regulatory reasons its future availability cannot be guaranteed. Please contact your local Siemens organization for further details.
You can find further information under www.siemens.com/syngo.via
Siemens AG (Berlin and Munich) is a global technology powerhouse that has stood for engineering excellence, innovation, quality, reliability and internationality for more than 165 years. The company is active in more than 200 countries, focusing on the areas of electrification, automation and digitalization. One of the world's largest producers of energy-efficient, resource-saving technologies, Siemens is No. 1 in offshore wind turbine construction, a leading supplier of combined cycle turbines for power generation, a major provider of power transmission solutions and a pioneer in infrastructure solutions as well as automation, drive and software solutions for industry. The company is also a leading provider of medical imaging equipment – such as computed tomography and magnetic resonance imaging systems – and a leader in laboratory diagnostics as well as clinical IT. In fiscal 2014, which ended on September 30, 2014, Siemens generated revenue from continuing operations of €71.9 billion and net income of €5.5 billion. At the end of September 2014, the company had around 357,000 employees worldwide on a continuing basis.
Further information is available on the Internet at www.siemens.com
Reference Number: PR2015060254HCEN
Mr. Thorsten Opderbeck
Tel: +49 (9131) 84-4906
Thorsten Opderbeck | Siemens Healthcare
3-D visualization of the pancreas -- new tool in diabetes research
15.03.2017 | Umea University
New PET radiotracer identifies inflammation in life-threatening atherosclerosis
02.03.2017 | Society of Nuclear Medicine
Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.
The results will be published on March 22 in the journal „Astronomy & Astrophysics“.
Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...
Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.
Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...
In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...
Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.
Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...
Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.
Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...
20.03.2017 | Event News
14.03.2017 | Event News
07.03.2017 | Event News
24.03.2017 | Materials Sciences
24.03.2017 | Physics and Astronomy
24.03.2017 | Physics and Astronomy